To further validate our screening results, cytarabine at different dosages was used to treat SK‐MEL‐28 melanoma cells, and the results showed that cytarabine repressed EEF2K, p‐STAT3 and SPP1 in a dose‐dependent manner (Figure 6J). This evidence concerns the gene EEF2K and melanoma.